Dimethyl fumarate induces cardiac developmental toxicity in zebrafish via down-regulation of oxidative stress

Toxicology. 2024 Mar:503:153735. doi: 10.1016/j.tox.2024.153735. Epub 2024 Jan 23.

Abstract

Dimethyl fumarate (DMF) is an immunosuppressant commonly used to treat multiple sclerosis and other autoimmune diseases. Despite known side effects such as lymphopenia, the effect of DMF on cardiac development remains unclear. To assess this, we used zebrafish to evaluate the cardiac developmental toxicity of DMF. Our study showed that DMF reduced the survival rate of zebrafish embryos, with those exposed to 1, 1.3, and 1.6 mg/L exhibiting heart rate reduction, shortened body length, delayed yolk sac absorption, pericardial edema, increased distance from sinus venous to bulbus arteriosus, and separation of cardiomyocytes and endocardial cells at 72 hpf. Heart development-related genes showed disorder, apoptosis-related genes were up-regulated, and the oxidative stress response was down-regulated. Treatment with cysteamine ameliorated the heart development defects. Our study demonstrates that DMF induces cardiac developmental toxicity in zebrafish, possibly by down-regulating oxidative stress responses. This study provides a certain research basis for further study of DMF-induced cardiac developmental toxicity, and provides some experimental evidence for future clinical application and study of DMF.

Keywords: Apoptosis; Cardiotoxicity; Dimethyl fumarate; Oxidative stress.

MeSH terms

  • Animals
  • Cardiotoxicity / metabolism
  • Dimethyl Fumarate / metabolism
  • Dimethyl Fumarate / toxicity
  • Down-Regulation
  • Embryo, Nonmammalian
  • Heart Defects, Congenital*
  • Oxidative Stress
  • Zebrafish* / physiology

Substances

  • Dimethyl Fumarate